Five clinical trials impacting blood cancers approved for funding
Cures Within Reach partnered with Goldman Philanthropic Partnerships, Leukemia Research Foundation and individual donors to fund these pivotal trials
CHICAGO - Aug. 8, 2023 - PRLog -- Cures Within Reach, a global nonprofit that identifies and funds clinical trials testing approved therapies for new uses, recently selected five clinical trials to impact blood cancers. Three are already ongoing and two more will be starting soon. This brings Cures Within Reach's oncology portfolio to 21 clinical trials: 11 ongoing trials, 7 recently completed and 3 selected/starting soon.
Five oncology clinical trials involving childhood and adult acute myeloid leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, relapsed lymphoma and myelofibrosis were selected in 2022 and 2023 as part of Cures Within Reach's Oncology and Rare Disease efforts. If these clinical trials are successful, these proof-of-concept trials could provide critical data for larger confirmatory studies or for future off-label clinical use.
Cures Within Reach pooled funds from the Goldman Philanthropic Partnerships, Leukemia Research Foundation and individual donors to fund these five clinical trials. This customized approach allows donors the ability to support a disease area (i.e. blood cancer), patient population (i.e. pediatrics) or geographic region, as well as the flexibility and control over their involvement during the selection process.
"We are proud to partner with Cures Within Reach on their blood cancer drug repurposing clinical trials, including a pediatric study focusing on acute myeloid leukemia (AML)," said Kevin Radelet, Executive Director of Leukemia Research Foundation. "This collaboration allows the opportunity to fast-track clinical testing for already approved drugs, which have the potential to produce better outcomes for children with AML."
"Our family foundation, Goldman Philanthropic Partnerships, was established to fund medical research that traditional funding sources overlooked, including for younger researchers, for rare disease and for drug repurposing, and Cures Within Reach has been a critical part of our mission since its inception in 2005," said Nanci Soriano of Goldman Philanthropic Partnerships. "Our family knows intimately the effects of blood cancer on patients and families, and we are thrilled to provide some of the funding for these five new blood cancer clinical trials."
"Cures Within Reach is pleased to support these low-risk, high-reward efforts to impact blood cancer patients and their families," said Barbara Goodman, President & CEO of Cures Within Reach. "We are playing a pivotal role in finding new treatments for unsolved diseases by providing funding for the first-in-human clinical trials required to reach more patients."
Respected research institutions across the U.S. have started or will start these 5 clinical trials:
About Cures Within Reach
Cures Within Reach (CWR) is a US-based nonprofit leader leveraging the speed, safety and cost-effectiveness of testing already approved therapies for new indications that improve patient quality and length of life, driving more treatments to more patients more quickly. CWR provides seed funds for first in-human or pivotal studies that, when successful, allow a catalytic effect of additional follow-on trials and follow-on funding to build evidence for publication, to allow clinicians to make their own decisions with their patients (called off-label use) or for regulatory approval by the FDA or other agencies. CWR's 2023 initiatives include focused efforts to impact Diversity, Equity & Inclusion; Veterans; and Pediatrics. CWR currently has a global portfolio of 41 funded trials at 34 institutions in 29 diseases in 8 countries. Visit cureswithinreach.org.